Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK3 | Q9Y572 | 3/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 5/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.37 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.37 |
| ▸ | PIM1 | P11309 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | PLAT | P00750 | 2/20 | 0.36 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | RORA | P35398 | 1/20 | 0.34 |
| ▸ | RORC | P51449 | 1/20 | 0.34 |
| ▸ | RORB | Q92753 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4921014 | 0.86 | CNR2 (0.44) | BRD4CREBBP | |
| SCHEMBL4916514 | 0.83 | CNR2 (0.48) | — | |
| SCHEMBL14144740 | 0.80 | BRD4 (0.46) | RIPK3BRD4CREBBP | |
| SCHEMBL4924369 | 0.80 | BRD4 (0.58) | BRD4CREBBP | |
| SCHEMBL4923434 | 0.80 | RIPK3 (0.44) | RIPK3BRD4CREBBPPLATEGLN1 | |
| SCHEMBL4924719 | 0.77 | BRD4 (0.44) | BRD4CREBBP | |
| SCHEMBL4923871 | 0.77 | CREBBP (0.64) | BRD4CREBBP | |
| SCHEMBL4923461 | 0.75 | CNR2 (0.47) | BRD4CREBBPHRH3 | |
| SCHEMBL4925689 | 0.74 | BRD4 (0.46) | RIPK3BRD4CREBBPHRH3 | |
| SCHEMBL4925735 | 0.74 | BRD4 (0.51) | BRD4CREBBPRORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008079316-A1 | TETRAHYDROQUINOLINONES, TETRAHYDRONAPHTHYRIDONES AND DERIVATIVES THEREOF | CARA THERAPEUTICS, INC. (US) | 2008-07-03 | — | — | WO | disclosed |
| US-20080161340-A1 | Tetrahydroquinilinones, tetrahydronaphthyridones and derivatives thereof | CARA THERAPEUTICS, INC. (US) | 2008-07-03 | — | — | US | disclosed |
| US-20080161340-A1 | Tetrahydroquinilinones, tetrahydronaphthyridones and derivatives thereof | CARA THERAPEUTICS, INC. (US) | 2008-07-03 | — | — | US | disclosed |
| US-20080161340-A1 | Tetrahydroquinilinones, tetrahydronaphthyridones and derivatives thereof | CARA THERAPEUTICS, INC. (US) | 2008-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161340-A1 | Tetrahydroquinilinones, tetrahydronaphthyridones and derivatives thereof | CNR1, CNR2, TRPV1 | RIPK3 1294/4885MCHR1 599/4885BRD4 407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.